Top

Published in:

01-06-2016 | Acute Lymphocytic Leukemias (K Ballen, Section Editor)

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults

Authors: Craig Speziali, Kristjan Paulson, Matthew Seftel

Published in: Current Hematologic Malignancy Reports | Issue 3/2016

Abstract

The majority of adults with acute lymphoblastic leukemia will achieve a first complete remission (CR). However relapse is the most common cause of treatment failure. Outcomes after relapse remain poor, with long-term survival in the order of 10 %. Treatment decisions made at the time of first complete remission are thus critical to ensuring long-term survival. Allogeneic hematopoietic cell transplant (HCT) is effective at preventing relapse in many transplant recipients but is also associated with significant treatment related morbidity and mortality. Alternatively, ongoing systemic chemotherapy offers lower toxicity at the expense of increased relapse rates. Over the past decades, both the safety of transplant and the efficacy of non-transplant chemotherapy have improved. Emerging data show substantially improved outcomes for young adults treated with pediatric-inspired chemotherapy regimens that question the role of HCT in the upfront setting. In this review, we review the data supporting the role of allogeneic transplantation in adult acute lymphoblastic leukemia (ALL), and we propose a therapeutic algorithm for upfront therapy of adults with ALL.

Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408–11. doi:10.1182/blood-2008-06-164863.CrossRefPubMed

Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–801. doi:10.1002/cncr.20668.CrossRefPubMed

Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–7. doi:10.1182/blood-2005-04-1623.CrossRefPubMed

4.•

Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation. Blood. 2008;111(4):1827–33. doi:10.1182/blood-2007-10-116582. The MRC/ECOG trial is the largest donor/no-donor study of alloHCT in ALL and helped establish alloHCT as standard of care.CrossRefPubMed

Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71(1):123–31. http://www.ncbi.nlm.nih.gov/pubmed/3422030. Accessed January 29, 2016.PubMed

Le Q-H, Thomas X, Ecochard R, et al. Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol. 2006;77(6):471–9. doi:10.1111/j.1600-0609.2006.00753.x.CrossRefPubMed

Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148(1):80–9. doi:10.1111/j.1365-2141.2009.07941.x.CrossRefPubMed

Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–76. doi:10.1182/blood-2011-09-377713.CrossRefPubMed

Nagafuji K, Miyamoto T, Eto T, et al. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol. 2013;6:14. doi:10.1186/1756-8722-6-14.CrossRefPubMedPubMedCentral

10.

Ravandi F, Jorgensen JL, O’Brien SM, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016;172(3):392–400. doi:10.1111/bjh.13834.CrossRefPubMed

11.

Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–21. doi:10.1182/blood-2012-11-466482.CrossRefPubMedPubMedCentral

12.

Zhou Y, Slack R, Jorgensen JL, et al. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14(4):319–26. doi:10.1016/j.clml.2014.01.002.CrossRefPubMed

13.

Bar M, Wood BL, Radich JP, et al. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment. 2014;2014:421723. doi:10.1155/2014/421723.PubMedPubMedCentral

14.

Tucunduva L, Ruggeri A, Sanz G, et al. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of. Br J Haematol. 2014;166(5):749–57. doi:10.1111/bjh.12970.CrossRefPubMed

15.••

Ribera J-M, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA. J Clin Oncol. 2014;32(15):1595–604. doi:10.1200/JCO.2013.52.2425. This is the first trial to direct assignment of alloHCT based on MRD status affter induction chemotherapy. Overall survival was improved for those who achieved MRD negative status and were treated with chemotherapy only.CrossRefPubMed

16.••

Dhédin N, Huynh A, Maury S, et al. Blood. 2015;125(16):2486–96. doi:10.1182/blood-2014-09-599894. quiz 2586. This study also demonstrates the prognostic significance of MRD status and showed that only patients with MRD positive disease derived benefit from alloHCT.

17.

Terwey TH, Hemmati PG, Nagy M, et al. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014;20(10):1522–9. doi:10.1016/j.bbmt.2014.05.026.CrossRefPubMed

18.

Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20(9):1307–13. doi:10.1016/j.bbmt.2014.04.018.CrossRefPubMed

19.

Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000;14(6):1353–66. x. http://www.ncbi.nlm.nih.gov/pubmed/11147227. Accessed January 31, 2016.CrossRefPubMed

20.

Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121(2):339–50. doi:10.1182/blood-2012-07-445098.CrossRefPubMedPubMedCentral

21.

Hocking J, Schwarer AP, Gasiorowski R, et al. Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leuk Lymphoma. 2014;55(12):2801–7. doi:10.3109/10428194.2014.894191.CrossRefPubMed

22.

DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526–34. doi:10.1038/leu.2014.229.CrossRefPubMedPubMedCentral

23.

Lepretre S, Touzart A, Vermeulin T, et al. Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study. J Clin Oncol. 2015. doi:10.1200/JCO.2015.61.5385.PubMed

24.••

Seftel MD, Neuberg D, Zhang M-J, et al. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome negative adult ALL in first complete remission. Am J Hematol. 2015. doi:10.1002/ajh.24285. This study demonstrates the improved outcomes for young adults treated with pediatric inspired chemotherapy protocols. A retrospective comparison with contemporaneous matched controls from the CIBMTR database demonstrated improved outcomes for those treated with chemotherapy alone.PubMed

25.

Liew E, Atenafu EG, Schimmer AD, et al. Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leuk Res. 2012;36(12):1517–20. doi:10.1016/j.leukres.2012.08.019.CrossRefPubMed

26.

Kako S, Kanamori H, Kobayashi N, et al. Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia. Br J Haematol. 2013;161(1):95–103. doi:10.1111/bjh.12225.CrossRefPubMed

27.

Thomas X, Boiron J-M, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–86. doi:10.1200/JCO.2004.10.050.CrossRefPubMed

28.

Hunault M, Harousseau J-L, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104(10):3028–37. doi:10.1182/blood-2003-10-3560.CrossRefPubMed

29.

Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer. 2010;116(14):3447–57. doi:10.1002/cncr.25136.CrossRefPubMed

30.

Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653–61. doi:10.3324/haematol.2014.118588.CrossRefPubMedPubMedCentral

31.

Ravandi F, O’Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–64. doi:10.1002/cncr.29646.CrossRefPubMed

32.

Kim D-Y, Joo Y-D, Lim S-N, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–56. doi:10.1182/blood-2015-03-636548.CrossRefPubMed

33.

Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19(1):150–5. doi:10.1016/j.bbmt.2012.08.021.CrossRefPubMed

34.

Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99(1):111–5. doi:10.3324/haematol.2013.085811.CrossRefPubMedPubMedCentral

35.

Giebel S, Labopin M, Gorin NC, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer. 2014;50(2):411–7. doi:10.1016/j.ejca.2013.08.027.

36.••

Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–9. doi:10.1182/blood-2015-02-627935. This study demonstrates the feasability of reduced intensity chemotherapy regimens for older adults with Ph+ALL who are treated with tyrosine kinase inhibitors. Outcomes were similar for patients treated with autoHCT or alloHCT among patients who achieved major molecular response.CrossRefPubMed

37.

Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254–62. doi:10.1038/leu.2012.352.CrossRefPubMed

38.

Marks DI, Woo KA, Zhong X, et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica. 2014;99(2):322–8. doi:10.3324/haematol.2013.094193.CrossRefPubMedPubMedCentral

39.

Matsumura T, Kami M, Yamaguchi T, et al. Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. Leukemia. 2012;26(7):1482–6. doi:10.1038/leu.2012.11.CrossRefPubMed

40.

Tucunduva L, Ruggeri A, Sanz G, et al. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(7):887–94. doi:10.1038/bmt.2014.72.CrossRefPubMed

41.

Yan C-H, Jiang Q, Wang J, et al. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2014;20(9):1314–21. doi:10.1016/j.bbmt.2014.04.011.CrossRefPubMed

42.

Sun Y-Q, Wang J, Jiang Q, et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL. Bone Marrow Transplant. 2015;50(1):20–5. doi:10.1038/bmt.2014.195.CrossRefPubMed

43.

Bachanova V, Marks DI, Zhang M-J, et al. Ph+ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658–65. doi:10.1038/leu.2013.253.CrossRefPubMedPubMedCentral

44.

Eom K-S, Shin S-H, Yoon J-H, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013;88(8):634–41. doi:10.1002/ajh.23465.CrossRefPubMed

45.

Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366–74. doi:10.1182/blood-2010-01-264077.CrossRefPubMedPubMedCentral

46.

Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22):4439–43. doi:10.1182/blood-2010-02-266551.CrossRefPubMed

47.

Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(2):303–6. doi:10.3324/haematol.11960.CrossRefPubMed

48.

Weisdorf D, Bishop M, Dharan B, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002;8(4):213–20. http://www.ncbi.nlm.nih.gov/pubmed/12014810. Accessed January 31, 2016.CrossRefPubMed

49.

Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36. doi:10.1002/cncr.28136.CrossRefPubMedPubMedCentral

50.

DeAngelo DJ, Stelljes M, Martinelli G, et al. Efficacy and safety of inotuzumab ozogamicin (INO) vs standard of care (SOC) in salvage 1 or 2 patients with acute lymphoblastic leukemia (ALL): an ongoing global phase 3 study. Late breaking abstract LB2073. Haematologica. 2015. http://learningcenter.ehaweb.org/eha/2015/20th/103387/daniel.deangelo.efficacy.and.safety.of.inotuzumab.ozogamicin.(ino).vs.standard.html?f=p3m3. Accessed February 5, 2016.

51.

Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40. doi:10.1200/JCO.2014.56.3247.CrossRefPubMed

52.

Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. doi:10.1016/S1470-2045(14)71170-2.CrossRefPubMed

53.

Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578–84. doi:10.1182/blood-2015-06-649111.CrossRefPubMedPubMedCentral

54.

Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–23. doi:10.1182/blood-2014-12-580068.CrossRefPubMedPubMedCentral

55.

Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program. 2014;2014(1):559–64. doi:10.1182/asheducation-2014.1.559.PubMed

56.

Amrolia PJ, Pule M. Chimeric antigen receptor T cells for ALL. Lancet. 2015;385(9967):488–90. doi:10.1016/S0140-6736(14)61729-3.CrossRefPubMed

Title: Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults
Authors: Craig Speziali
Kristjan Paulson
Matthew Seftel
Publication date: 01-06-2016
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 3/2016
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-016-0317-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy

The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies

Nuances in the Management of Older People With Multiple Myeloma

Management of Patients with MYC-Altered Lymphomas

Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials